Skip to content

Member

Stine BOSSE

Renew · Denmark

Group
Renew
Country
Denmark
Roll-call participation
97.6 %ⓘ of 5 928 roll calls in office · chamber median 90.2 % · whole term, roll calls
With majority line
97.8 %ⓘ of 5 781 votes where the group had a line · Renew median 95.5 %
More facts (5)
National party
M Moderaterne
In office
Since 16 Jul 2024
Against clear line
82 of 5 621 votesⓘ
Committees
BUDG (substitute), ENVI, SANT (vice-chair)
Member id
257020
More

Record

The member’s figures against the median of their group and of the chamber. Each vote counts the member in the group they belonged to that day.

Roll-call participation ⓘ

97.6 %

5 786 of 5 928 roll calls while in office

Renew median: 90.4 % (+7.2 pts)

Chamber median: 90.2 %

With majority line ⓘ

97.8 %

5 652 of 5 781 votes where their group had a line

Renew median: 95.5 % (+2.3 pts)

Against clear line ⓘ

1.5 %

82 of 5 621 votes where their group had a clear line

57 opposite (for ↔ against), 25 abstained against the line

Abstention ⓘ

0.8 %

47 of 5 786 votes cast

Participation 97.6 % — Renew median 90.4 %, 76 members.ⓘ
Data as a table
Participation among the 76 members of the Renew with enough votes.
FigureParticipation
Stine BOSSE97.6 %
Renew median90.4 %
Lowest in the group65.3 %
Highest in the group99.7 %
Members76
With majority line 97.8 % — Renew median 95.5 %, 76 members.ⓘ
Data as a table
With majority line among the 76 members of the Renew with enough votes.
FigureWith majority line
Stine BOSSE97.8 %
Renew median95.5 %
Lowest in the group77.5 %
Highest in the group98.3 %
Members76
  • Whole term, 5 928 roll-call votes. The dots are the other members of Renew; no ranks.
  • “No vote recorded” is not the same as absent: leave, illness and chairing the sitting look the same.
  • A group’s line is inferred from its members’ votes — Parliament publishes no whip.

Votes, 5 928

Export

Every roll-call vote of the term with the member’s position, newest first.

Result: for–against–abstained. Majority line: how most of the member’s group voted that day (“Tie” when no position won). ≠ group marks a vote otherwise than a clear line (at least two thirds, with at least 10 members voting) of their group.
DateDecision and voteResultPositionMajority line
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement (Resolution) Final vote — text as a wholeAdopted 434 for, 49 against, 168 abstainedPosition: For Majority line: For
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement (Resolution) Amendment 12, adding text after paragraph 12 72 for, 522 against, 51 abstainedPosition: Against Majority line: Against
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement Final vote on the draft Council decisionConsent given 473 for, 114 against, 58 abstainedPosition: For Majority line: For
9 Sept 2025EU-Brazil Agreement: cooperation with and through Europol and the Federal Police of Brazil Final vote on the draft Council decisionConsent given 606 for, 5 against, 19 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Final votePassed 431 for, 145 against, 76 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 395 to recital 19 187 for, 442 against, 16 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 409 + 417 (voted as one) to Annex VII, Part C, point 16 208 for, 431 against, 7 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 371 to Annex VII, Part C, point 13 530 for, 112 against, 4 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 408 + 416 (voted as one) to Annex VII, Part C, point 6 204 for, 438 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 407 to Annex VII, Part C, point 4 137 for, 447 against, 61 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 318 to Article 55, après le paragraph 2 512 for, 120 against, 14 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 390 to Article 55, après le paragraph 2 105 for, 538 against, 3 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 389 to Article 38, paragraph 3, après le point b 96 for, 549 against, 3 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 388 to Article 18, paragraph 1 124 for, 515 against, 7 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 387 to Article 7, après le paragraph 4 207 for, 431 against, 10 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 137 to Article 6, paragraph 3, alinéa 1 — part 2 451 for, 182 against, 10 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 137 to Article 6, paragraph 3, alinéa 1 — part 1 461 for, 185 against, 5 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 394 to Article 6, paragraph 1, après l'alinéa 2 142 for, 496 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 403 to Article 6, paragraph 1, alinéa 2 192 for, 442 against, 11 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 130 to Article 6, paragraph 1, alinéa 1 444 for, 189 against, 14 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 402 to Article 6, paragraph 1, alinéa 1 194 for, 434 against, 15 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 393 to Article 6, paragraph 1, alinéa 1 120 for, 529 against, 2 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 150 to Article 6 — part 2 438 for, 196 against, 8 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 150 to Article 6 — part 1 452 for, 195 against, 2 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 134 to Article 6 473 for, 154 against, 22 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 133 to Article 6 — part 2 512 for, 122 against, 15 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 133 to Article 6 — part 1 505 for, 126 against, 19 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 401 to Article 6 131 for, 447 against, 72 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 392 to Article 4, après le paragraph 1 138 for, 504 against, 4 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 391 to Article 4, paragraph 1, après le point b 138 for, 508 against, 2 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 399 + 412 (voted as one) to Article 3, paragraph 1, point 15 168 for, 445 against, 36 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 398 to Article 3, paragraph 1, après le point 9 199 for, 437 against, 11 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 397 to Article 3, paragraph 1, point 9 158 for, 471 against, 17 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 396 to Article 2, paragraph 6, partie introductive 197 for, 418 against, 30 abstainedPosition: Against Majority line: Against
8 Sept 2025Wednesday’s agenda – Request by the PPE Group Ordre du jour de mercredi — Demande du groupe PPE 384 for, 10 against, 51 abstainedPosition: No vote recorded Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Final vote — text as a wholeAdopted 523 for, 75 against, 14 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 1 to paragraph 14 157 for, 428 against, 36 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 8, adding text after paragraph 13 95 for, 420 against, 119 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Paragraph 13 — part 2 483 for, 84 against, 67 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 7 to paragraph 13 80 for, 407 against, 151 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 6, adding text after paragraph 12 79 for, 531 against, 18 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 5 to paragraph 10 47 for, 560 against, 27 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 4 to paragraph 8 88 for, 520 against, 22 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 3, adding text after paragraph 2 63 for, 552 against, 15 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 2, adding text after paragraph 1 123 for, 390 against, 110 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Final vote — text as a wholeAdopted 494 for, 83 against, 71 abstainedPosition: For Majority line: For
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Amendment 2, adding text after recital S 217 for, 409 against, 23 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Amendment 1, adding text after citation 2 226 for, 409 against, 17 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Paragraph 34 — part 2 566 for, 60 against, 23 abstainedPosition: For Majority line: For
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Paragraph 32 — part 1 588 for, 56 against, 7 abstainedPosition: For Majority line: For

Show all 50 votes on this page

Roll-call participation

One cell per sitting while in office, shaded by the share of that day’s roll calls the member voted in. The official attendance register is kept separately by Parliament.

No vote recorded on 12 of 107 sittings with roll calls.

"No vote recorded" is not the same as absent: leave, illness and chairing the sitting look the same.

Data as a table
Roll calls held at each sitting while in office and how many of them the member voted in.
SittingRoll callsVoted in
17 Jul 20242321
18 Jul 202411
16 Sept 202421
18 Sept 202422
19 Sept 20249291
7 Oct 202422
8 Oct 202411
9 Oct 20241818
10 Oct 202444
21 Oct 202422
22 Oct 20241010
23 Oct 2024129127
24 Oct 20241313
13 Nov 202422
14 Nov 20243636
25 Nov 202420
26 Nov 20241818
27 Nov 20241111
28 Nov 20245756
17 Dec 20241313
18 Dec 20243333
19 Dec 2024450
20 Jan 202522
21 Jan 202511
22 Jan 202522
23 Jan 20254545
10 Feb 202510
11 Feb 20253232
12 Feb 20251010
13 Feb 20253029
10 Mar 202520
11 Mar 202590
12 Mar 2025228227
13 Mar 20252424
31 Mar 202533
1 Apr 20253535
2 Apr 2025251249
3 Apr 20256262
5 May 202550
6 May 20251010
7 May 2025220217
8 May 202510395
21 May 202521
22 May 20255353
16 Jun 202520
17 Jun 20254141
18 Jun 20259191
19 Jun 20258787
7 Jul 202510
8 Jul 20255555
9 Jul 2025134132
10 Jul 20253636
8 Sept 202510
9 Sept 2025101101
10 Sept 20253434
11 Sept 20256969
6 Oct 202522
7 Oct 202554
8 Oct 20255554
9 Oct 20256565
20 Oct 202530
21 Oct 20251313
22 Oct 2025186186
23 Oct 20255555
13 Nov 2025267265
24 Nov 202533
25 Nov 20257574
26 Nov 2025100100
27 Nov 2025125124
15 Dec 202540
16 Dec 20256666
17 Dec 20254343
18 Dec 20254231
20 Jan 20266764
21 Jan 2026112112
22 Jan 20265858
9 Feb 202622
10 Feb 20263838
11 Feb 20261313
12 Feb 2026141139
24 Feb 20264343
9 Mar 202611
10 Mar 2026197196
11 Mar 20266060
12 Mar 20263434
25 Mar 202633
26 Mar 20266969
27 Apr 202622
28 Apr 2026225224
29 Apr 2026296294
30 Apr 20266867
18 May 202644
19 May 202632
20 May 20269696
21 May 20269898
15 Jun 202622
16 Jun 20264039
17 Jun 2026127125
18 Jun 20267777
6 Jul 202622
7 Jul 20267270
8 Jul 2026144143
9 Jul 20266767
14 Sept 202610
15 Sept 2026155151
16 Sept 20268078
17 Sept 2026124123

Voting neighbours

Members who voted the same way most often in the roll calls they both took part in, within and outside the member’s group (group at the date of each vote), over all roll calls of the term.

At least 200 shared roll calls over at least six months in office together. Within = both sat in the same group on the date of the vote; a member who changed group can appear on both lists. Baseline = the median agreement of all pairs of members of the groups the two sat in on the date of each shared vote (within: the group they shared; outside: the two groups), weighted by the votes they shared in each combination.

Within Renew

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in the same group (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of that group.
SelectMemberGroupCountryAgreementBaseline
Dainius ŽALIMAS RenewLithuania96 % of 5 396 shared92 %
Anna-Maja HENRIKSSON RenewFinland96 % of 5 156 shared92 %
Dan BARNA RenewRomania96 % of 5 083 shared92 %
Ilhan KYUCHYUK RenewBulgaria96 % of 5 372 shared92 %
Raquel GARCÍA HERMIDA-VAN DER WALLE RenewNetherlands96 % of 5 772 shared92 %
Marjan ŠAREC RenewSlovenia96 % of 5 150 shared92 %
Gerben-Jan GERBRANDY RenewNetherlands96 % of 5 708 shared92 %
Michał KOBOSKO RenewPoland96 % of 5 300 shared92 %
Vlad VASILE-VOICULESCU RenewRomania96 % of 4 877 shared92 %
Nikola MINCHEV RenewBulgaria96 % of 5 431 shared92 %

Outside the group

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in different groups (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of the groups the two sat in on those votes (groups at the date, weighted by the votes shared in each combination).
SelectMemberGroupCountryAgreementBaseline
Dan NICA S&DRomania90 % of 3 529 shared86 %
Birgit SIPPEL S&DGermany89 % of 4 578 shared86 %
Sven MIKSER S&DEstonia89 % of 5 697 shared86 %
Iratxe GARCÍA PÉREZ S&DSpain89 % of 5 391 shared86 %
Carla TAVARES S&DPortugal89 % of 5 327 shared86 %
Isilda GOMES S&DPortugal89 % of 5 132 shared86 %
Marina KALJURAND S&DEstonia89 % of 5 403 shared86 %
Tobias CREMER S&DGermany88 % of 5 332 shared86 %
Liesbet SOMMEN EPPBelgium88 % of 5 589 shared82 %
Vilija BLINKEVIČIŪTĖ S&DLithuania88 % of 5 463 shared86 %

Work

Seats in committees, delegations and intergroups, and the dossiers the member leads, shadows or negotiates.

Seats

Body: the committee, delegation or intergroup, with its kind. Role: the member’s role in it. From, To: the dates of the seat (“now” while it lasts).
BodyRoleFromTo
Committee on BudgetsBUDG CommitteeSubstitute19 Jul 2024now
Committee on the Environment, Climate and Food SafetyENVI CommitteeMember20 Jan 2025now
Committee on Public HealthSANT CommitteeVice-chair29 Jan 2025now
Delegation to the EU-North Macedonia Joint Parliamentary CommitteeD-MK Joint parliamentary committeeSubstitute19 Sept 2024now
Delegation for relations with the Pan-African ParliamentDPAP DelegationVice-chair9 Oct 2024now
Delegation to the Africa-EU Parliamentary AssemblyDAFR Parliamentary assemblySubstitute9 Apr 2026now
Intergroup on Attracting Investment to Ensure a Competitive and Sustainable European UnionIG10-03 Intergroup / working groupChair co31 Jan 2025now
Intergroup on Cancer and Rare DiseasesIG10-05 Intergroup / working groupChair co27 Jan 2025now
Intergroup on Children’s RightsIG10-06 Intergroup / working groupMember19 Feb 2025now
Intergroup on Resilience, Disaster Management and Civil ProtectionIG10-19 Intergroup / working groupVice-chair17 Mar 2025now

Show all 18 seats

Dossiers

Dossier: the procedure the declaration names (“No dossier named” for a delegation without one). Role: rapporteur, shadow rapporteur, negotiator or delegation. Committee: the committee that appointed them. Date: of the declaration.
DossierRoleCommitteeDate
No dossier namedOfficial delegationSANT11 Sept 2026
Neurological health strategyShadow rapporteurSANT15 Jul 2026
Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act)Shadow rapporteur for an opinionENVI26 Feb 2026
Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act)Shadow rapporteurSANT26 Feb 2026
Amending Directives 2001/18/EC and 2010/53/EU as regards the placing on the market of genetically modified micro-organisms and the processing of organsShadow rapporteurSANT26 Feb 2026
Establishing the Connecting Europe Facility for the period 2028-2034, amending Regulation (EU) 2024/1679 and repealing Regulation (EU) 2021/1153Shadow rapporteur for an opinionBUDG26 Feb 2026
Amending Decision (EU) 2021/1764 on the Association of the Overseas Countries and Territories with the European Union including relations between the European Union on the one hand, and Greenland and the Kingdom of Denmark on the otherShadow rapporteur for an opinionBUDG26 Feb 2026
Establishing the European Competitiveness Fund ('ECF’), including the specific programme for defence research and innovation activitiesOpinion rapporteurBUDG15 Jan 2026
Establishing the European Competitiveness Fund ('ECF’), including the specific programme for defence research and innovation activitiesOpinion rapporteurENVI14 Jan 2026
Establishing the European Competitiveness Fund ('ECF’), including the specific programme for defence research and innovation activitiesShadow rapporteur for an opinionSANT14 Jan 2026

Show all 25 dossier roles

Topics they work on (model-assigned)

Counts: dossiers they spoke on, led or amended, and their questions and motions.

In the chamber

Speeches and statements in plenary debates, newest first; the verbatim report is on Parliament’s site.

48 contributions recorded; 8 on behalf of their group; 53 minutes of speaking time.

Date: the sitting. Debate: the item debated, and the group when they spoke on its behalf. Kind: speech or written statement, with speaking time. Verbatim: the verbatim report on Parliament’s site.
DateDebateKindVerbatim
17 Sept 2026An EU health workforce crisis plan: sustainability of healthcare systems and employment and working conditions in the healthcare sector (debate) Speech · 2 minRead
15 Sept 2026Acceleration of permit-granting for defence readiness projects (Omnibus V) - Simplification of intra-EU transfers of defence-related products and simplification of security and defence procurement (Omnibus V) - Defence readiness and facilitating defence investments and conditions for the defence industry (Omnibus V) Speech · 1 minRead
15 Sept 2026Acceleration of permit-granting for defence readiness projects (Omnibus V) - Simplification of intra-EU transfers of defence-related products and simplification of security and defence procurement (Omnibus V) - Defence readiness and facilitating defence investments and conditions for the defence industry (Omnibus V) SpeechRead
15 Sept 2026Acceleration of permit-granting for defence readiness projects (Omnibus V) - Simplification of intra-EU transfers of defence-related products and simplification of security and defence procurement (Omnibus V) - Defence readiness and facilitating defence investments and conditions for the defence industry (Omnibus V) Speech · 1 minRead
8 Jul 2026Harnessing the potential of a competitive and sustainable EU Bioeconomy Strategy for EU strategic autonomy (debate) Speech · 1 minRead
8 Jul 2026Harnessing the potential of a competitive and sustainable EU Bioeconomy Strategy for EU strategic autonomy (debate) Speech · 1 minRead
8 Jul 2026Ebola outbreak in the Democratic Republic of the Congo and Uganda: EU solidarity and preparedness in global health (debate) Speech · 1 minRead
21 May 2026The Union’s preparedness for and response to health emergencies: the case of the MV Hondius and the hantavirus warning (debate) on behalf of RenewSpeech · 1 minRead
20 May 2026Financing EU priorities in a sustainable, predictable and resilient way through a new EU own resource from the online gambling and betting services sector (debate) on behalf of RenewSpeech · 1 minRead
20 May 2026Reviewing the ETS system to support European competitiveness (topical debate) Speech · 1 minRead

Show all 40 recent contributions

Questions and motions, 23

Parliamentary questions and motions for resolutions the member authored or co-signed, newest first.

Date: tabled. Title: the question or motion, with its id. Kind: written question or motion for a resolution, with the number of co-authors. Answer: the date of the answer to a question.
DateTitleKindAnswer
6 Jul 2026MOTION FOR A RESOLUTION on Ongoing persecution of Christians in Nigeria, notably the Kawel village massacre B-10-2026-0353Motion for a resolutionwith 16 co-authors—
1 Jul 2026PROPOSAL FOR A DECISION requesting the Authority for European Political Parties and European Political Foundations to verify whether Europe of Sovereign Nations Party complies with the conditions laid down in Article 3(1), points (d) and (e), of Regulation (EU, Euratom) 2025/2445 B-10-2026-0338Motion for a resolutionwith 246 co-authors—
5 Feb 2026When and how will the Commission deliver on its commitment to revise the EU’s animal welfare legislation? O-10-2026-000006Oral questionwith 35 co-authorsNot yet answered
3 Feb 2026Ensuring patient safety for all Europeans: the need to establish a warning system for disqualified medical professionals E-10-2026-000428Written questionwith 24 co-authors27 Mar 2026
14 Jan 2026EU response to recent US statements concerning Colombia, Mexico, Cuba and Greenland, and respect for international law and treaties E-10-2026-000146Written questionwith 23 co-authors16 Mar 2026
8 Dec 2025Value added tax on sport and fitness services – impact on public health and prevention of lifestyle-related diseases E-10-2025-004847Written questionwith 8 co-authors23 Feb 2026
19 Nov 2025MOTION FOR A RESOLUTION on protection of EU consumers against the practices of certain e-commerce platforms: the case of child-like sex dolls, weapons and other illegal products and materials B-10-2025-0500Motion for a resolutionwith 71 co-authors—
24 Oct 2025Actions of the Commission concerning the Russian shadow fleet P-10-2025-004199Priority written questionwith 2 co-authors21 Nov 2025
20 Oct 2025MOTION FOR A RESOLUTION on renewing the EU-Africa partnership: building common priorities ahead of the Angola Summit B-10-2025-0475Motion for a resolutionwith 13 co-authors—
6 Oct 2025MOTION FOR A RESOLUTION on a united response to recent Russian violations of the EU Member States’ airspace and critical infrastructure B-10-2025-0422Motion for a resolutionwith 20 co-authors—

Show all 23 questions and motions

Amendments tabled in committee, 106

Committee amendment documents that carry amendments by the member, with how many are theirs.

Date: of the amendment document. Text amended: the dossier and the document’s id. Committee: where the amendments were tabled. Amendments: how many in the document are the member’s.
DateText amendedCommitteeAmendments
30 Sept 2026General budget of the European Union for the financial year 2027 - all sections BUDG-AM-796264 BUDG12
10 Sept 2026Amending Directives 2001/18/EC and 2010/53/EU as regards the placing on the market of genetically modified micro-organisms and the processing of organs CJ64-AM-792138 CJ649
10 Sept 2026Amending Directives 2001/18/EC and 2010/53/EU as regards the placing on the market of genetically modified micro-organisms and the processing of organs CJ64-AM-792139 CJ6416
28 Jul 2026Amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and amending Regulation (EU) 2022/123 as regards the support of the European Medicines Agency for the expert panels on medical devices and Regulation (EU) 2024/1689 as regards the list of Union harmonisation legislation referred to in its Annex I SANT-AM-791891 SANT22
28 Jul 2026Amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and amending Regulation (EU) 2022/123 as regards the support of the European Medicines Agency for the expert panels on medical devices and Regulation (EU) 2024/1689 as regards the list of Union harmonisation legislation referred to in its Annex I SANT-AM-791887 SANT14
28 Jul 2026Amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and amending Regulation (EU) 2022/123 as regards the support of the European Medicines Agency for the expert panels on medical devices and Regulation (EU) 2024/1689 as regards the list of Union harmonisation legislation referred to in its Annex I SANT-AM-791890 SANT20
15 Jul 2026General budget of the European Union for the financial year 2027 - all sections SANT-AM-789117 SANT11
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790939 CJ5343
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790953 CJ5312
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790936 CJ5354

Show all 106 amendment documents

Connections

Dossiers they lead or shadow, committees, party, delegation and other related pages.

Political group

  • Group Renew Europe Renew · Centre · liberalism, pro-Europeanism

National delegation

  • Delegation Denmark National delegation

Sources & citation

Where the facts on this page come from, and how to cite it.

Data source
Licensed CC BY 4.0.
Data version
data version 7669c786bb14 (1 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1 · methods
Retrieved
1 October 2026

Cite as

EU Parl Watch Research (2026). “Stine BOSSE”. Member record. memberId 257020. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/members/257020?nb=all&page=77&vscope=all (retrieved 1 October 2026). Official source: Member’s profile, European Parliament, https://www.europarl.europa.eu/meps/en/257020. Data: EP Open Data: member record, https://data.europarl.europa.eu/api/v2/meps/257020?format=application%2Fld%2Bjson (CC BY 4.0); data version 7669c786bb14 (1 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1.
BibTeX
@misc{epw-member-257020,
  author = {{EU Parl Watch Research}},
  title = {{Stine BOSSE}},
  year = {2026},
  howpublished = {\url{https://news.eu-parl.st-solutions.dev/members/257020?nb=all&page=77&vscope=all}},
  url = {https://news.eu-parl.st-solutions.dev/members/257020?nb=all&page=77&vscope=all},
  urldate = {2026-10-01},
  publisher = {EU Parl Watch Research},
  note = {Member record. memberId 257020. Official source: https://www.europarl.europa.eu/meps/en/257020. Data: EP Open Data: member record (CC BY 4.0); data version 7669c786bb14 (1 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1}
}